Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **mitochondrial oxidative phosphorylation machinery** (OXPHOS machinery) consists of a series of multi-subunit protein complexes—Complex I (NADH-ubiquinone oxidoreductase), Complex II (succinate-ubiquinone oxidoreductase), Complex III (ubiquinone-cytochrome c oxidoreductase), Complex IV (cytochrome c oxidase), and ATP synthase—embedded in the mitochondrial inner membrane[1][4][2][3]. These complexes operate in concert to transfer electrons from metabolic substrates (NADH, FADH2) through the electron transport chain, pumping protons across the inner membrane to generate a proton motive force. This gradient is then used by ATP synthase to convert ADP and inorganic phosphate into ATP, the main cellular energy currency[2][1][4]. Dysfunction or genetic alterations in OXPHOS components lead to a broad spectrum of diseases, including inherited mitochondrial disorders, neurodegeneration, certain cancers, and heart diseases[1][3]. Exposure to environmental toxins, certain drugs, or mutations can inhibit or disrupt the function of these complexes, causing impaired energy production and elevated oxidative stress. OXPHOS machinery is considered a core therapeutic target for modulating bioenergetics in cancer, metabolic disorders, and aging-related conditions, but targeting this system also carries significant safety risks due to its fundamental role in cellular metabolism[1][3][4]. **Note:** - This target is often considered *too broad* for therapeutic purposes, as it represents a collection of complexes and enzymes rather than a single protein. Individual complexes (e.g., Complex I, ATP synthase) are usually targeted specifically, not the whole machinery at once[2][4]. - "Mitochondrial oxidative phosphorylation machinery" is not a standardized name for a single molecular entity, but refers to a collective system, which compromises specificity for drug targeting and biomarker selection[1][3].
Inhibition of electron transport chain complexes (I–IV); Inhibition of ATP synthase; Uncoupling oxidative phosphorylation (proton gradient dissipation); Modulation of ROS production
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial oxidative phosphorylation machinery (OXPHOS machinery).